Cellectar Biosciences, Inc. (CLRB) Earnings History
Net Loss22 years of earnings data (2004–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cellectar Biosciences, Inc. (CLRB) Earnings Overview
As of November 9, 2026, Cellectar Biosciences, Inc. (CLRB) reported trailing twelve-month net income of -$22M, reflecting +80.1% year-over-year growth. The company earned $-1.82 per diluted share over the past four quarters.
Looking at the long-term picture, CLRB's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2010.
Cellectar Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RNAC (-$130M net income, -4658.6% margin), RMD ($1.59B net income, 26.9% margin), AGEN ($28M net income, 0.1% margin), CLRB has comparable earnings metrics. Compare CLRB vs RNAC →
CLRB Earnings vs Peers
Earnings metrics vs comparable public companies
CLRB Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$22M | +51.1% | -$23M | $-8.35 | - | - |
| 2024 | -$45M | -4.2% | -$52M | $-41.89 | - | - |
| 2023 | -$43M | -34.5% | -$39M | $-104.99 | - | - |
| 2022 | -$32M | -31.8% | -$29M | $-135.18 | - | - |
| 2021 | -$24M | -59.8% | -$24M | $-130.35 | - | - |
| 2020 | -$15M | -7.1% | -$15M | $-228.55 | - | - |
| 2019 | -$14M | -6.4% | -$14M | $-550.86 | - | - |
| 2018 | -$13M | +2.4% | -$13M | $-1567.96 | - | - |
| 2017 | -$14M | -119.4% | -$14M | $-3210.00 | - | - |
| 2016 | -$6M | -12.5% | -$9M | $-6420.00 | - | - |
| 2015 | -$5M | +32.2% | -$9M | $-21090.00 | - | - |
| 2014 | -$8M | +24.8% | -$10M | $-53100.00 | - | - |
| 2013 | -$11M | -22.6% | -$12M | $-114000.00 | - | - |
| 2012 | -$9M | -18.3% | -$9M | $-138000.00 | - | - |
| 2011 | -$7M | -454.8% | -$7M | $-186000.00 | - | - |
| 2010 | $2M | +109.4% | -$5M | $-999999.00 | 6286.1% | -16351.7% |
| 2009 | -$22M | -35.4% | -$10M | $-999999.00 | -23125.7% | -10620.6% |
| 2008 | -$16M | +15.9% | -$17M | $-999999.00 | -13060.0% | -13170.8% |
| 2007 | -$20M | -136.0% | -$20M | $-999999.00 | - | - |
| 2006 | -$8M | -171.4% | -$9M | $-999999.00 | - | - |
| 2005 | -$3M | -274.5% | -$5M | $-999999.00 | -24264.1% | -40428.3% |
| 2004 | $-815,285 | - | $-625,219 | $-183600.00 | -16430.6% | -12600.1% |
Download Data
Export CLRB earnings history in CSV or JSON format
Free sign-in required to download data
CLRB Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CLRB — Frequently Asked Questions
Quick answers to the most common questions about buying CLRB stock.
What is CLRB earnings per share (EPS)?
CLRB trailing twelve-month (TTM) diluted EPS is $-1.82, reflecting +80.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2004 to 2025 is available in the table on this page.
What is Cellectar Biosciences, Inc.'s net income?
Cellectar Biosciences, Inc. (CLRB) trailing twelve-month net income is $-22M as of 2025. Earnings grew +80.1% year-over-year.
Is CLRB profitable?
CLRB is not currently profitable on a TTM basis, reporting a net loss of $-22M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CLRB's earnings growth rate?
CLRB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2004 to 2025.
What are CLRB's profit margins?
Cellectar Biosciences, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -180.0%.
Is CLRB growing earnings?
Yes, CLRB earnings are accelerating — EPS growth of +80.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-22M. Earnings momentum is strengthening.
What was CLRB's best earnings year?
Cellectar Biosciences, Inc.'s highest annual net income on record is $2M, achieved in fiscal year 2010. Earnings history on this page spans 2004 to 2025 and includes all annual and quarterly figures.
What were CLRB's earnings last quarter?
CLRB's most recent reported quarter was Q2 2026. Net income was $-7M with diluted EPS of $-0.57. For a full breakdown of all quarters, see the quarterly earnings table on this page.